A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic colorectal Cancer
This phase II trial studies how well savolitinib works in treating participants with MET amplified colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Ages: 18 and older
- Sexes: All
- Accepts healthy volunteers?: No
Contact the study team
Additional eligibility criteria and study procedure details can be explained by the study team. Please call or email:
Principal InvestigatorThomas George, MD, FACP
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.